TIMP3 and type 1 diabetes mellitus: The results showed that 12 weeks after STZ administration, 87% (14/16) of wt mice exhibited hyperglycemia compared to 45% (9/20) of MacT3 mice, indicating that TIMP3 overexpression in cells of the myeloid lineage significantly reduced the susceptibility to type 1 diabetes (p < 0.01) (Figure 1A).